文献速递类风湿关节炎

甲氨蝶呤治疗临床可疑关节痛:哪些患者亚临床关节炎症改善最明显

Which arthralgia patients benefit most in reduction of subclinical joint inflammation by methotrexate treatment: results from the TREAT EARLIER trial.
PubMed 文献 · RMD Open · 2026-01-20

TREAT EARLIER 试验纳入有亚临床炎症的临床可疑关节痛(CSA)患者,随机接受肌注糖皮质激素加 1 年甲氨蝶呤治疗。115 例治疗患者中 44 例(38%)在 12 个月时达到 MRI 定义的应答;基线亚临床炎症严重程度(尤其多部位腱鞘炎伴/不伴骨炎)可预测应答,而基线临床变量无独立关联。

要点

  • 38% 的 CSA 治疗患者在 12 个月达到 MRI 定义的亚临床关节炎症应答。
  • 基线腱鞘炎和骨炎水平越高,甲氨蝶呤治疗应答可能性越大。
  • ≥2 个部位腱鞘炎或骨炎合并腱鞘炎者阳性预测值高(77%、79%)。

核心结论

  • 对有亚临床炎症的 CSA 患者,甲氨蝶呤治疗第一年应答最好者可由诊断时较高的亚临床炎症水平识别,主要归因于多部位腱鞘炎伴或不伴骨炎。

研究设计与样本

  • TREAT EARLIER 试验中,有亚临床炎症的 CSA 患者随机接受肌注糖皮质激素注射和 1 年甲氨蝶呤疗程。
  • 治疗应答定义为 12 个月时 MRI 检测的滑膜炎、腱鞘炎或骨炎水平下降超过最小可检测变化。

主要发现

  • 115 例治疗患者中 44 例(38%)达到 MRI 定义的治疗应答。
  • 应答患者疼痛和身体功能也显著改善(疼痛视觉模拟评分 -22,健康评估问卷 -0.29)。
  • 基线临床变量与治疗应答无独立关联,而亚临床关节炎症严重程度有关。
  • 腱鞘炎和骨炎水平尤其具有预测性。
  • ≥2 个部位腱鞘炎或骨炎合并腱鞘炎(且至少 1 项特征在 ≥2 个部位)者阳性预测值高(PPV 77%、79%)。

关键数值与推荐

  • 治疗应答:12 个月时 MRI 检测的滑膜炎、腱鞘炎或骨炎水平下降超过最小可检测变化。
  • ≥2 个部位腱鞘炎者 PPV 77%;骨炎合并腱鞘炎且至少 1 项特征在 ≥2 个部位者 PPV 79%。

临床怎么用

  • 对 CSA 且有亚临床炎症的患者,基线 MRI 显示多部位腱鞘炎伴或不伴骨炎者可能从甲氨蝶呤治疗中更多获益。
  • 基线临床变量不宜单独用于筛选甲氨蝶呤治疗应答者,应结合影像学亚临床炎症评估。
  • ACPA 状态不影响上述影像学特征对治疗应答的预测价值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The TREAT EARLIER trial showed in clinically suspect arthralgia (CSA) that methotrexate induced reductions in subclinical inflammation and related disease burden during the year of treatment, which was sustained thereafter. We studied whether the treatment response defined at the level of subclinical joint inflammation was present in all treated CSA patients and, if not, what characterises the subgroup of responders. METHODS: CSA patients with subclinical inflammation were randomised to receive an intramuscular glucocorticoid injection and a 1-year course of methotrexate. Treatment response was defined as a reduction of MRI-detected synovitis, tenosynovitis or osteitis levels beyond the smallest detectable change at 12 months. Baseline clinical and imaging characteristics were studied in relation to treatment response. Predictive values were determined. RESULTS: 44 of 115 (38%) treated patients had an MRI-defined treatment response. These patients also significantly improved in pain and physical functioning (-22 Visual Analogue Scale pain, -0.29 Health Assessment Questionnaire). Baseline clinical variables were not independently associated with this response, in contrast to the severity of subclinical joint inflammation. Tenosynovitis and osteitis levels in particular were predictive. Patients with ≥2 sites with tenosynovitis or a combination of osteitis and tenosynovitis (with ≥1 of these features at ≥2 sites) had high positive predictive values (PPV 77%, 79%). PPVs were similar in ACPA-positive and ACPA-negative patients at increased risk for rheumatoid arthritis (RA). CONCLUSIONS: CSA patients with subclinical inflammation who responded best to methotrexate during the first year were identified by increased levels of subclinical inflammation at diagnosis, primarily due to multiple sites of tenosynovitis with/without osteitis. These data may contribute to personalised medicine for arthralgia at risk for RA.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Claassen S, Dumoulin QA, Glas HK, et al. Which arthralgia patients benefit most in reduction of subclinical joint inflammation by methotrexate treatment: results from the TREAT EARLIER trial. RMD Open. 2026. PMID: 41558803. doi:10.1136/rmdopen-2025-006102

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。